PriceTargets.com logo

Monte Rosa Therapeutics - GLUE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.40
  • Forecasted Upside: 150.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.36 As of 03/30/2023 01:00 AM ET
▼ -0.16 (-2.13%)

This chart shows the closing price for GLUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Monte Rosa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLUE

Analyst Price Target is $18.40
▲ +150.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Monte Rosa Therapeutics in the last 3 months. The average price target is $18.40, with a high forecast of $22.00 and a low forecast of $11.00. The average price target represents a 150.00% upside from the last price of $7.36.

This chart shows the closing price for GLUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Monte Rosa Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Credit Suisse GroupLower TargetNeutral$12.00 ➝ $11.00Low
1/2/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$18.00Low
11/16/2022Credit Suisse GroupLower Target$12.00N/A
10/13/2022UBS GroupInitiated CoverageBuy$22.00Low
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$20.00Low
5/11/2022Piper SandlerLower Target$40.00 ➝ $21.00High
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$19.00High
2/10/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$19.00High
1/3/2022GuggenheimLower Target$40.00 ➝ $35.00Low
11/17/2021Berenberg BankInitiated CoverageBuyLow
10/14/2021SVB LeerinkInitiated CoverageMarket Perform$20.00High
7/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
7/19/2021GuggenheimInitiated CoverageBuy$30.00High
7/19/2021Piper SandlerInitiated CoverageOverweight$40.00High
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Monte Rosa Therapeutics logo
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $7.36
Low: $7.23
High: $7.69

50 Day Range

MA: $6.80
Low: $5.95
High: $8.21

52 Week Range

Now: $7.36
Low: $5.74
High: $15.52

Volume

78,271 shs

Average Volume

138,342 shs

Market Capitalization

$363.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Monte Rosa Therapeutics?

The following Wall Street analysts have issued research reports on Monte Rosa Therapeutics in the last year: Credit Suisse Group AG, Jefferies Financial Group Inc., Piper Sandler, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for GLUE.

What is the current price target for Monte Rosa Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Monte Rosa Therapeutics in the last year. Their average twelve-month price target is $18.40, suggesting a possible upside of 150.0%. UBS Group AG has the highest price target set, predicting GLUE will reach $22.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $11.00 for Monte Rosa Therapeutics in the next year.
View the latest price targets for GLUE.

What is the current consensus analyst rating for Monte Rosa Therapeutics?

Monte Rosa Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLUE will outperform the market and that investors should add to their positions of Monte Rosa Therapeutics.
View the latest ratings for GLUE.

What other companies compete with Monte Rosa Therapeutics?

Other companies that are similar to Monte Rosa Therapeutics include Vigil Neuroscience, AlloVir, Ambrx Biopharma, Aura Biosciences and Tarsus Pharmaceuticals. Learn More about companies similar to Monte Rosa Therapeutics.

How do I contact Monte Rosa Therapeutics' investor relations team?

The company's listed phone number is 617-949-2643 and its investor relations email address is [email protected] The official website for Monte Rosa Therapeutics is www.monterosatx.com. Learn More about contacing Monte Rosa Therapeutics investor relations.